Observational study of spinal muscular atrophy type I and implications for clinical trials
Top Cited Papers
- 26 August 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 83 (9), 810-817
- https://doi.org/10.1212/wnl.0000000000000741
Abstract
Objectives: Prospective cohort study to characterize the clinical features and course of spinal muscular atrophy type I (SMA-I). Methods: Patients were enrolled at 3 study sites and followed for up to 36 months with serial clinical, motor function, laboratory, and electrophysiologic outcome assessments. Intervention was determined by published standard of care guidelines. Palliative care options were offered. Results: Thirty-four of 54 eligible subjects with SMA-I (63%) enrolled and 50% of these completed at least 12 months of follow-up. The median age at reaching the combined endpoint of death or requiring at least 16 hours/day of ventilation support was 13.5 months (interquartile range 8.1–22.0 months). Requirement for nutritional support preceded that for ventilation support. The distribution of age at reaching the combined endpoint was similar for subjects with SMA-I who had symptom onset before 3 months and after 3 months of age (p = 0.58). Having 2 SMN2 copies was associated with greater morbidity and mortality than having 3 copies. Baseline electrophysiologic measures indicated substantial motor neuron loss. By comparison, subjects with SMA-II who lost sitting ability (n = 10) had higher motor function, motor unit number estimate and compound motor action potential, longer survival, and later age when feeding or ventilation support was required. The mean rate of decline in The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders motor function scale was 1.27 points/year (95% confidence interval 0.21–2.33, p = 0.02). Conclusions: Infants with SMA-I can be effectively enrolled and retained in a 12-month natural history study until a majority reach the combined endpoint. These outcome data can be used for clinical trial design.This publication has 22 references indexed in Scilit:
- Glucose metabolism and pancreatic defects in spinal muscular atrophyAnnals of Neurology, 2012
- Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and IIIJournal of Child Neurology, 2011
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliabilityNeuromuscular Disorders, 2010
- The changing natural history of spinal muscular atrophy type 1Neurology, 2007
- 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy11–13 February 2005Naarden, The NetherlandsNeuromuscular Disorders, 2005
- The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiationHuman Molecular Genetics, 2005
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005
- Spinal muscular atrophy 32nd ENMC international workshop Naarden, The Netherlands, 10–12 March 1995Neuromuscular Disorders, 1996
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995